Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
GRCE
Upturn stock ratingUpturn stock rating

Grace Therapeutics, Inc. (GRCE)

Upturn stock ratingUpturn stock rating
$3.08
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/14/2025: GRCE (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

2 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $11.65

1 Year Target Price $11.65

Analysts Price Target For last 52 week
$11.65 Target price
52w Low $1.75
Current$3.08
52w High $4.97

Analysis of Past Performance

Type Stock
Historic Profit -44.2%
Avg. Invested days 29
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/14/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 34.98M USD
Price to earnings Ratio -
1Y Target Price 11.65
Price to earnings Ratio -
1Y Target Price 11.65
Volume (30-day avg) 2
Beta 1.37
52 Weeks Range 1.75 - 4.97
Updated Date 08/9/2025
52 Weeks Range 1.75 - 4.97
Updated Date 08/9/2025
Dividends yield (FY) -
Basic EPS (TTM) -1.29

Earnings Date

Report Date 2025-08-12
When -
Estimate -
Actual -0.2111

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -15.16%
Return on Equity (TTM) -22.89%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 11977520
Price to Sales(TTM) -
Enterprise Value 11977520
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -
Shares Outstanding 10139900
Shares Floating 4952308
Shares Outstanding 10139900
Shares Floating 4952308
Percent Insiders 38.39
Percent Institutions 20.59

ai summary icon Upturn AI SWOT

Grace Therapeutics, Inc.

stock logo

Company Overview

overview logo History and Background

Grace Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative gene therapies for rare and orphan diseases. It was founded in 2018. The company's focus is on developing new treatment methods using gene therapy for diseases that affect people globally.

business area logo Core Business Areas

  • Gene Therapy Development: Focused on developing and commercializing gene therapies for rare and orphan diseases. Includes pre-clinical and clinical research and development efforts.
  • Research and Development: Conducts research and development activities to discover and advance novel gene therapy candidates.

leadership logo Leadership and Structure

The company is led by a team of experienced biopharmaceutical executives and scientists with expertise in gene therapy development. The company's leadership team includes experienced professionals with expertise in gene therapy, clinical development, and regulatory affairs.

Top Products and Market Share

overview logo Key Offerings

  • GT-102: A gene therapy candidate for the treatment of GBA-Parkinson's Disease. Currently in clinical trials. Market share is currently 0%, as it is in clinical trials. Competitors include Prevail Therapeutics and Lysogene.
  • GT-202: A gene therapy candidate for the treatment of ALS (Amyotrophic Lateral Sclerosis) for SOD1 mutation. Currently in pre-clinical trials. Market share is currently 0%, as it is in pre-clinical trials. Competitors include Biogen and Ionis Pharmaceuticals.

Market Dynamics

industry overview logo Industry Overview

The gene therapy market is experiencing significant growth, driven by technological advancements, increasing regulatory approvals, and growing demand for personalized medicine. The industry faces challenges related to manufacturing complexities, high treatment costs, and regulatory hurdles.

Positioning

Grace Therapeutics is positioned as a player in the rare and orphan disease gene therapy space. Its competitive advantage lies in its expertise in developing innovative gene therapy approaches for diseases with limited treatment options.

Total Addressable Market (TAM)

The gene therapy market is projected to reach billions of dollars. Grace Therapeutics is focusing on niche segments within this market, targeting specific rare diseases. TAM for Parkinson's (GBA) is estimated to be $5 Billion. TAM for ALS is estimated to be $2.5 Billion.

Upturn SWOT Analysis

Strengths

  • Innovative gene therapy platform
  • Focus on rare and orphan diseases
  • Experienced management team
  • Strong intellectual property portfolio

Weaknesses

  • Limited financial resources
  • Early-stage clinical development
  • High research and development costs
  • Dependence on regulatory approvals

Opportunities

  • Growing demand for gene therapies
  • Increasing regulatory support
  • Potential for strategic partnerships
  • Expansion into new therapeutic areas

Threats

  • Competition from larger pharmaceutical companies
  • Regulatory challenges
  • Manufacturing complexities
  • High treatment costs

Competitors and Market Share

competitor logo Key Competitors

  • Biogen (BIIB)
  • Ionis Pharmaceuticals (IONS)
  • Prevail Therapeutics (Acquired by Eli Lilly - LLY)
  • Lysogene (LYS)

Competitive Landscape

Grace Therapeutics faces competition from larger, more established pharmaceutical companies. Its advantages include its focus on rare diseases and innovative gene therapy platform. Disadvantages include limited financial resources and early-stage clinical development.

Growth Trajectory and Initiatives

Historical Growth: Grace Therapeutics' historical growth is defined by its progress in developing and advancing its gene therapy pipeline.

Future Projections: Future growth is dependent on the successful completion of clinical trials, regulatory approvals, and commercialization of its gene therapy candidates. Analyst estimates are not publicly available at this early stage.

Recent Initiatives: Recent initiatives include advancing GT-102 and GT-202 through clinical trials and securing additional funding.

Summary

Grace Therapeutics is a promising gene therapy company focused on rare diseases, with innovative technology but it faces challenges due to its early stage, limited funding, and competition from larger companies. The successful execution of its clinical trials and strategic partnerships will be crucial for its growth. The company has a focused approach and an experienced team, which are strong assets. Potential investors will watch for clinical trial results and funding developments.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Website
  • ClinicalTrials.gov
  • Press Releases

Disclaimers:

The data provided is for informational purposes only and should not be considered investment advice. Market share estimates are approximate and based on available data. Ratings are based on current company information and industry data and are not indicative of future performance.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Grace Therapeutics, Inc.

Exchange NASDAQ
Headquaters Princeton, NJ, United States
IPO Launch date 2024-10-08
CEO & Director Mr. Prashant Kohli
Sector Healthcare
Industry Biotechnology
Full time employees 6
Full time employees 6

Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray of betamethasone to improve neurological symptoms of Ataxia-Telangiectasia (A-T) and GTX-101, a topical bioadhesive film-forming polymer for the treatment of pain associated with postherpetic neuralgia (PHN). The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. Grace Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.